Navigation Links
Use of anti-depressants during pregnancy not linked with increased risk of stillbirth, infant death
Date:1/1/2013

CHICAGO In a study that included nearly 30,000 women from Nordic countries who had filled a selective serotonin reuptake inhibitor (SSRI) prescription during pregnancy, researchers found no significant association between use of these medications during pregnancy and risk of stillbirth, neonatal death, or postneonatal death, after accounting for factors including maternal psychiatric disease, according to a study in the January 2 issue of JAMA.

"Depression during pregnancy is common with prevalences ranging between 7 percent and 19 percent in economically developed countries. Maternal depression is associated with poorer pregnancy outcomes, including increased risk of preterm delivery, which in turn may cause neonatal morbidity and mortality," according to background information in the article. "Use of selective serotonin reuptake inhibitors during pregnancy has been associated with congenital anomalies, neonatal withdrawal syndrome, and persistent pulmonary hypertension of the newborn. However, the risk of stillbirth and infant mortality when accounting for previous maternal psychiatric disease remains unknown."

Olof Stephansson, M.D., Ph.D., of the Karolinska Institutet, Stockholm, Sweden and colleagues conducted a study to examine whether SSRI exposure during pregnancy was associated with increased risks of stillbirth, neonatal death, and postneonatal death. The study included women with single births from all Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) at different periods from 1996 through 2007. The researchers obtained information on maternal use of SSRIs from prescription registries; maternal characteristics, pregnancy, and neonatal outcomes were obtained from patient and medical birth registries. The authors estimated relative risks of stillbirth, neonatal death, and postneonatal death associated with SSRI use during pregnancy taking into account maternal characteristics and previous psychiatric hospitalization.

Among 1,633,877 singleton births in the study, there were 6,054 stillbirths; 3,609 neonatal deaths; and 1,578 postneonatal deaths. A total of 29,228 (1.79 percent) of mothers had filled a prescription for an SSRI during pregnancy. The researchers found that women exposed to an SSRI had higher rates of stillbirth (4.62 vs. 3.69 per 1000) and postneonatal death (1.38 vs. 0.96 per 1000) than those who did not. The rate of neonatal death was similar between groups (2.54 vs. 2.21 per 1000). "Yet in multivariate models, SSRI use was not associated with stillbirth, neonatal death, or postneonatal death. Estimates were further attenuated when stratified by previous hospitalization for psychiatric disease," the authors write.

"The present study of more than 1.6 million births suggests that SSRI use during pregnancy was not associated with increased risks of stillbirth, neonatal death, or postneonatal death. The increased rates of stillbirth and postneonatal mortality among infants exposed to an SSRI during pregnancy were explained by the severity of the underlying maternal psychiatric disease and unfavorable distribution of maternal characteristics such as cigarette smoking and advanced maternal age."

"However, decisions regarding use of SSRIs during pregnancy must take into account other perinatal outcomes and the risks associated with maternal mental illness," the researchers conclude.


'/>"/>

Contact: Olof Stephansson
olof.stephansson@ki.se
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Economic environment during infancy linked with substance use, delinquent behavior in adolescence
2. Tips on Coping With Grief During Holidays
3. Doctors Advice People to Get Zoster Vaccine During Winters – VyGone Introduces Ultimate Zoster Vaccine
4. Mesothelioma Victims Center Will Be Open During The Holidays To Make Certain All Victims Of Mesothelioma or their Family Members Get To The Best Mesothelioma Law Firms
5. ProvidaStaff,LLC Reports on Increased Travel Therapy & PRN Career Opportunities During The Holidays
6. US Drug Watchdog Urges Victims Of A Transvaginal Mesh Product Failure To Call them For The Names Of The Best Possible Women Attorneys-During The Holidays
7. Carolina Women's Physicians Gives Key Tips for Eating Healthy During the Holiday Season
8. Healthy lifestyle during menopause may decrease breast cancer risk later on
9. MyBloodWorks Creator Glen Ogle Comments on New Study Linking Hypertension During Pregnancy to Later Heart Trouble
10. Egyptian Pharaohs Throat Was Slashed During Coup, Research Suggests
11. Keep Your Dog Safe During Hectic Holiday Season: Expert
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Aliso Viejo, CA (PRWEB) , ... May 03, 2016 , ... ... use in Final Cut Pro X. Pixel Film Studios’ titles allow users to add ... animations and basic elements such as boxes, lines and accents. To add greater contrast, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Today at its Annual Technology ... D. Pulido, R.Ph., Co-Founder of NCPDP and member of the NCPDP Foundation Board ... IT Specialist, Office of the National Coordinator for Health Information Technology (ONC). NCPDP’s ...
(Date:5/3/2016)... ... ... For over 23 years, Doctors on Liens has committed to ... and therapists treating personal injury patients on a lien basis. With the recent addition ... in Santa Monica, Doctors on Liens is continuing that tradition. While the network ...
(Date:5/3/2016)... ... ... With the opioid epidemic now at the forefront, attention has shifted away from ... its misuse causes long-term consequences for all aspects of society, from the disastrous effects ... and older. In addition, there is the long term affects of chronic liver ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... today announced that it has been honored as one of the nation’s most ... 2016 InformationWeek Elite 100. Horizon received the recognition for technology achievements that have ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... SAN FRANCISCO , May 2, 2016 /PRNewswire/ ...  is expected to reach USD 11.1 billion by ... Grand View Research, Inc. Major drivers of the ... in therapeutic areas and government recommendations for periodic ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:4/29/2016)... PARIS , April 29, 2016 ... Jérôme Contamine, Directeur Financier ... la santé, publie ses résultats pour ... Financier du Groupe, Jérôme Contamine, commente ... Groupe et les perspectives pour le ...
Breaking Medicine Technology: